(... ih-brih-TOO-moh-mab ty-UK-seh-tan) A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. 90Y-ibritumomab tiuxetan contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. 90Y-ibritumomab tiuxetan is a type of radioimmunoconjugate. Also called 90Y-Zevalin, IDEC-Y2B8, and yttrium Y 90-ibritumomab tiuxetan.
Learn more about 90Y-ibritumomab tiuxetan
Latest research (Pubmed)